Reduced-nicotine cigarettes were beneficial in reducing nicotine exposure and dependence, and also the number of cigarettes smoked per day, when compared with standard-nicotine cigarettes in a six-week study published in the New England Journal of Medicine.

A signaling factor called Wnt10b is a novel target for optimizing cardiac repair after a heart attack.

The initial results of a landmark clinical trial sponsored by the National Institutes of Health (NIH) indicate lowering systolic blood pressure below a commonly recommended target significantly reduces rates of cardiovascular events and lowers risk of death in a group of adults 50 years and older.

Vanderbilt University researchers have received two major federal grants — totaling $7.6 million over four years — to support groundbreaking research aimed at making genetic information a routine part of patients’ electronic medical records.

The Vanderbilt Institute for Clinical and Translational Research (VICTR) is partnering with a public charity, Cures Within Reach, to encourage “rediscovery research,” the “repurposing” of already approved medical treatments to other conditions or diseases for which there are no “universally” effective therapies.

Joshua Beckman, M.D., MSc., previously a faculty member at Harvard Medical School and Brigham and Women’s Hospital, has been named director of Vanderbilt’s newly formed Section of Vascular Medicine within the Division of Cardiovascular Medicine.

Understanding how signaling molecules are transported within and out of the cell may help to uncover the causes of certain cancers.